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A Meta-Analysis of Randomized Controlled Trials
Comparing Irinotecan/Platinum with Etoposide/Platinum in
Patients with Previously Untreated Extensive-Stage Small
Cell Lung Cancer
Jingwei Jiang, MM,*† Xiaohua Liang, MD,*† Xinli Zhou, MD,*† Lizhen Huang, MS,‡
Ruofan Huang, MD,*† Zhaohui Chu, MM,*† and Qiong Zhan, MM*†
Purpose: To compare the efficacy and toxicities of irinotecan/
platinum (IP) with etoposide/platinum (EP) in patients with
previously untreated extensive-stage small cell lung cancer
(E-SCLC).
Methods: The PubMed database, the Cochrane Library, conference
proceedings, databases of ongoing trials, and references of published
trials and review articles were searched. Two reviewers indepen-
dently assessed the quality of the trials and extracted data. The
relative risk for overall response to treatment, hazard ratios (HRs)
for overall survival (OS) and progression-free survival (PFS), and
odds ratios for the different types of toxicity were pooled by STATA
package.
Results: Six trials involving 1476 patients with previously un-
treated E-SCLC were ultimately analyzed. The intention-to-
treatment analysis indicated that IP regimens could acquire more
overall response than EP regimens (relative risk  1.10, 95%
confidence interval CI: 1.00–1.21, p  0.043). The pooled HR
showed that IP could prolong OS (HR  0.81, 95% CI: 0.66–
0.99, p  0.044). Nevertheless, the pooled HR failed to show a
favorable PFS in IP regimens (HR  0.82, 95% CI: 0.64–1.06,
p  0.139). IP regimens led to less grade 3 to 4 anemia,
neutropenia, and thrombocytopenia but more grade 3 to 4 vom-
iting and diarrhea than EP regimens. Treatment-related deaths
were comparable between the two groups.
Conclusion: Although the PFS was similar from this meta-analysis,
our results suggest that IP might have an advantage in overall
response and OS compared with EP with less hematological toxic-
ities. The IP regimens may be an alternative of EP regimens in the
first-line treatment of E-SCLC.
Key Words: Small cell lung carcinoma, Irinotecan, Etoposide,
Platinum, Meta-analysis.
(J Thorac Oncol. 2010;5: 867–873)
Small cell lung cancer (SCLC) accounts for approximately15% of new cases of lung cancer diagnosed annually and
for up to 25% of lung cancer deaths each year.1 In 2008,
approximately 32,000 new cases of SCLC will be diagnosed
in the United States.2 When compared with non-small cell
lung cancer, SCLC generally has a shorter doubling time, a
higher growth fraction, and earlier progress of widespread
metastases. Most patients with SCLC present with hematog-
enous metastases, and approximately two-thirds of patients
present with extensive disease. Median survival was 12
weeks for untreated patients with limited-stage SCLC and 6
weeks for extensive-stage SCLC (E-SCLC). The 5-year sur-
vival is 15 to 25% for patients with limited-stage SCLC and
less than 1% for patients with E-SCLC. SCLC is highly
sensitive to initial chemotherapy and radiotherapy. In patients
with E-SCLC, chemotherapy alone can release symptoms and
prolong survival in most patients. The most commonly used
initial combination chemotherapy regimen is etoposide and
cisplatin (EP).1,3 In 2000, Japanese investigators reported
superior results with the topoisomerase I inhibitor irinotecan
combined with cisplatin (IP) compared with standard EP
regimen in a randomized phase III trial comprising 154
patients with E-SCLC. The study was prematurely closed
after two interim analyses. Median survival time was 12.8
months in the IP arm compared with 9.4 months in the EP
arm (p  0.002).4,5 Hermes et al.6 also found that irinotecan
plus carboplatin prolonged survival in E-SCLC with slightly
better scores for quality of life. Another randomized con-
trolled trial (RCT) showed that IP seemed to improve pro-
gression-free survival (PFS) with less toxicities than EP in
patients with E-SCLC.7 Therefore, IP regimen was recom-
mended for first-line treatment for patient with E-SCLC by
National Comprehensive Cancer Network guidelines.3 How-
ever, two subsequent and larger studies failed to confirm the
positive results.8,9 The role of IP regimen in E-SCLC remains
controversial. The objectives of this meta-analysis were to
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compare the efficacy and toxicities of IP with EP in patients
with previously untreated E-SCLC.
PATIENTS AND METHODS
Searching
In April 2009, an electronic search of the PubMed
database and the CENTRAL (the Cochrane Central Reg-
ister of Controlled Trials) database was performed. The
following keywords were used: “small cell lung cancer” or
“small cell lung carcinoma.” The search was limited in
“randomized controlled trial.” The published languages
and years were not limited. The American Society of Clinical
Oncology (ASCO) and European Society for Medical Oncology
annual meeting abstracts were also searched in the latest 10
years. Reference lists of original articles and review articles were
also examined for additional trials. The Physician Data Query
and ClinicalTrials.gov (http://clinicaltrials.gov) were searched to
identify ongoing studies.
Selection of Trials
Trials were eligible if they had compared the IP regi-
mens (irinotecan combined with cisplatin or carboplatin) to
EP regimens (etoposide plus cisplatin or carboplatin) in
patients with previously untreated E-SCLC. Patients had to
have pathologically confirmed SCLC and clinically diag-
nosed extensive-stage disease. Published and unpublished
trials, full texts and abstracts, and randomized II and III trials
were included. Trials were excluded if they did not meet with
above inclusion criteria.
Validity Assessment
An open assessment of the trials was performed using
the methods reported by Jadad et al.,10 which assessed the
trials according to the three questions: (1) whether reported
an appropriate randomization method (0–2 scores); (2)
whether reported an appropriate blinding method (0–2
scores); (3) whether reported withdrawals and dropouts (0–1
score).
Data Abstraction
All the data were independently abstracted by two
investigators (J.J. and L.H.) with the use of standardized data
abstraction forms. Disagreements were resolved by discus-
sion with an independent expert (X.L.). The following infor-
mation were sought from each article, although some articles
did not contain all the information as followed: first author;
year of publication; quality scores according to the method by
Jadad et al.10 study period; number of the patients; number of
the patients eligible for response evaluation; performance
status; median age; chemotherapy regimens; number of the
patients acquire overall response; hazard ratios (HRs) for
overall survival (OS) and PFS and their 95% confidence
intervals (CIs); specific grade 3 to 4 toxicity data such as
anemia, neutropenia, thrombocytopenia, vomiting, and diar-
rhea; and treatment-related deaths. If HR was not directly
reported, estimation of the log HR and variance from the
Kaplan-Meier curves was based on published methodology.11
Statistical Analysis
The relative risk (RR) for overall response to treatment,
HRs for OS and PFS, and odds ratios (ORs) for the different
types of toxicity were calculated using STATA SE 10.1
package (StataCorp, College Station, TX). Intention-to-treat-
ment (ITT) analysis was performed for overall response, OS,
and PFS and treatment-received analyses for toxicities. A
statistical test with a p value less than 0.05 was considered
significant. RR more than 1 reflects more overall response in
IP arm, HR more than 1 reflects more deaths or progression
in IP arm, and OR more than 1 indicates more toxicities in IP
arm; and vice versa. To investigate for statistical heterogene-
ity between trials, the standard 2 Q test was applied (mean-
ingful differences between studies indicated by p  0.10).
The results were generated using the fixed-effects model. A
random-effect model was employed when there was evidence
of significant statistical heterogeneity, generating a more
conservative estimate.12 All p values were two sided. All CIs
had a two-sided probability coverage of 95%.
Publication Bias
A number of steps were included in the study design to
minimize the potential for publication bias. The search strat-
egy was extensive. In addition, publication bias was not
found according to funnel plot, Begg’s test (p  1.000), and
Egger’s test (p  0.588).
RESULTS
Trial Flow
Two thousand sixty-four reports were retrieved origi-
nally after electronic searching, and 134–9,13–19 reports were
identified after scanning the titles and abstracts. Seven4,14–19
reports were excluded for following reasons: five4,14–17 were
preliminary meeting reports of Noda et al.,5 Hermes et al.,6
Schmittel et al.,7 Hanna et al.,8 and Lara et al. 9 and another
two18,19 were ongoing studies. Thus, six trials5–9,13 involv-
ing 1476 patients with E-SCLC were ultimately analyzed
(Figure 1).
FIGURE 1. Flow of identifying the trials comparing irinote-
can/platinum with etoposide/platinum in patients with previ-
ously untreated extensive-stage small cell lung cancer.
Jiang et al. Journal of Thoracic Oncology • Volume 5, Number 6, June 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer868
Characteristics of the Six Trials
Six randomized controlled trials5–9,13 meeting the inclu-
sion criteria were identified. Among them, two trials were phase
II RCTs.7,13 There was only one double-blinded trial.13 All the
six trials were reported in full text. Baseline characteristics of the
six trials are listed in Table 1. In total, 1476 patients with
E-SCLC were randomized to receive IP (792 patients) or EP
chemotherapy (684 patients). Two trials6,7 used carboplatin, and
the other used cisplatin.5,8,9,13 The quality of the six trials was
assessed using the three-question instrument reported by Jadad
et al.10 The quality scores are also listed in Table 1.
Response
Hermes et al.6 reported complete response only (18 of 105
in IP versus 7 of 104 in EP) and did not report partial response;
therefore, the overall response case numbers were presented in
five trials.5,7–9,13 The intention-to-treat analysis indicated that IP
regimens could acquire more overall response than EP regimens
(RR  1.10, 95% CI: 1.00–1.21, p  0.043; Figure 2). There
was no heterogeneity (2 2.53; p 0.640), and the pooled RR
for overall response was performed using fixed-effort model.
Because there was little difference in overall response
between cisplatin-based and carboplatin-based regimens pre-
sented by our preceding meta-analysis in advanced non-small
cell lung cancer,20 a subgroup meta-analysis and sensitivity
analysis was performed after the trial7 using carboplatin was
excluded. The subgroup meta-analysis and sensitivity analysis
did not confirm above result (RR  1.10, 95% CI: 0.99–1.21,
p  0.065; Figure 2). There was no heterogeneity (2  2.37,
p  0.499).
FIGURE 2. The meta-analysis showed that irino-
tecan/platinum (IP) regimens could acquire more
overall response than etoposide/platinum (EP)
regimens in patients with previously untreated
extensive-stage small cell lung cancer (p 
0.043), but the subgroup meta-analysis and sensi-
tivity analysis after the trial using carboplatin was
excluded failed to show an advantage in IP regi-
mens (p  0.065). CBP, irinotecan/carboplatin
compared with etoposide/carboplatin subgroup;
DDP, irinotecan/cisplatin compared with etopo-
side/cisplatin subgroup.
TABLE 1. Characteristics of the Six Trails Comparing Irinotecan/Platinum with Etoposide/Platinum in Patients with Previously
Untreated Extensive-Stage Small Cell Lung Cancer
Author
Quality
(Scores) Regimens n
Eligible for
Evaluation Male (%) PS 0–1 (%)
Median
Age
Lara et al.9 2 I-60 mg/m2 d1, 8, 15  P-60 mg/m2 d1, q4w 324 324 58 100 62
E-100 mg/m2 d1-3  P-80 mg/m2 d1, q3w 327 327 55 100 63
Hermes et al.6 2 I-175 mg/m2 d1  P*-AUC 4 d1, q3w 105 105 63 53 67
E#-120 mg/m2 d1-5  P*-AUC 4 d1, q3w 104 104 69 52 68
Schmittel et al.7 3 I-50 mg/m2 d1, 8, 15  P*-AUC 5 d1, q4w 35 33 71 74a 59
E-140 mg/m2 d1-3  P*-AUC 5 d1, q3w 35 34 71 71a 63
Pan et al.13 4 I-80 mg/m2 d1, 8, 15  P-27 mg/m2 d1-3, q4w 30 30 80 100 54
E-120 mg/m2 d1-3  P-27 mg/m2 d1-3, q3w 31 31 74 100 51
Hanna et al.8 2 I-65 mg/m2 d1, 8  P-30 mg/m2 d1, 8, q3w 221 221 58 92 63
E-120 mg/m2 d1-3  P-60 mg/m2 d1, q3w 110 110 57 88 62
Noda et al.5 2 I-60 mg/m2 d1, 8, 15  P-60 mg/m2 d1, q4w 77 77 82 92 63
E-100 mg/m2 d1-3  P-80 mg/m2 d1, q3w 77 77 90 87 63
I, irinotecan; E, etoposide; E#, oral etoposide; P, cispaltin; P*, carboplatin; PS, performance status by Zubrod-ECOG-WHO; ECOG, Eastern Cooperative Oncology Group; WHO,
World Health Organization.
a Performance status by Karnofsky score 80.
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Overall Survival
HRs for OS data were available for four trials including
1345 patients.5,6,8,9 The pooled HR for OS showed that IP
might be likely to prolong OS in patients with previously
untreated E-SCLC (HR  0.81, 95% CI: 0.66–0.99, p 
0.044; Figure 3). There was significant heterogeneity (2 
14.96; p  0.029), and the pooled HR for OS was performed
using random-effort model.
The subgroup meta-analysis and sensitivity analysis
after the trial6 using carboplatin was excluded failed to show
an advantage in IP regimen (HR  0.85, 95% CI: 0.67–1.07,
p  0.163; Figure 3). There was also significant heterogene-
ity (2  6.46; p  0.040).
Progression-Free Survival
HRs for PFS data were also available for four trials
including 1206 patients.5,7–9 The pooled HR for PFS failed to
display a difference between IP and EP regimens (HR  0.82,
95% CI: 0.64–1.06, p  0.139; Figure 4). There was significant
heterogeneity (2  14.24; p  0.003), and the pooled HR for
PFS was performed using random-effort model.
The subgroup meta-analysis and sensitivity analysis
after the trial7 using carboplatin was excluded also achieved
above result (HR  0.88, 95% CI: 0.68–1.15, p  0.354;
Figure 4). There was also significant heterogeneity (2 
10.62; p  0.005).
Toxicities
Hematological Toxicities
All the six trials reported grade 3 to 4 hematological
toxicities such as anemia, neutropenia, and thrombocytopenia
(Figure 5). The IP regimens led to less grade 3 to 4 anemia,
neutropenia, and thrombocytopenia than EP regimens (OR 
0.51, 95% CI: 0.36–0.72, p  0.000; OR  0.26, 95% CI:
FIGURE 3. The pooled hazard ratio showed that
irinotecan/platinum (IP) could prolong overall sur-
vival in patients with previously untreated exten-
sive-stage small cell lung cancer (p  0.044), but
the subgroup meta-analysis and sensitivity analysis
after the trial using carboplatin was excluded
failed to show an advantage in IP regimens (p 
0.163). CBP, irinotecan/carboplatin compared
with etoposide/carboplatin subgroup; DDP, irino-
tecan/cisplatin compared with etoposide/cisplatin
subgroup.
FIGURE 4. The pooled hazard ratio for progres-
sion-free survival failed to display a difference be-
tween irinotecan/platinum and etoposide/plati-
num regimens in patients with previously
untreated extensive-stage small cell lung cancer
(p  0.139). CBP, irinotecan/carboplatin com-
pared with etoposide/carboplatin subgroup; DDP,
irinotecan/cisplatin compared with etoposide/cis-
platin subgroup.
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0.12–0.54, p  0.000; OR  0.29, 95% CI: 0.20–0.41, p 
0.000, respectively).
Nonhematological Toxicities
All the six trials reported grade 3 to 4 diarrhea, one
trial6 did not report grade 3 to 4 vomiting and only four
trials5,7,9,13 reported treatment-related deaths, in which one
trial13 reported zero treatment related deaths in both groups
and were excluded when analyzed treatment-related death
(Figure 6). The results showed that IP regimens led to more
grade 3 to 4 vomiting and diarrhea than EP regimens (OR 
1.51, 95% CI: 1.01–2.25, p  0.044; OR  10.52, 95% CI:
FIGURE 5. The pooled odds ratios for hemato-
logical toxicities showed irinotecan/platinum regi-
mens led to less grade 3 to 4 anemia, neutrope-
nia, and thrombocytopenia than etoposide/
platinum regimens (p  0.000, 0.000, and 0.000,
respectively).
FIGURE 6. The pooled odds ratios for nonhe-
matological toxicities showed irinotecan/platinum
regimens led to more grade 3 to 4 vomiting and
diarrhea than etoposide/platinum regimens, and
treatment related deaths were comparable be-
tween two groups (p  0.044, 0.000, and 0.301,
respectively).
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5.94–18.65, p  0.000; respectively). Treatment-related deaths
were comparable between the two groups (OR 1.51, 95% CI:
0.69–3.30, p  0.301).
The toxicities of chemotherapy were described as case
number experienced grade 3 to 4 toxicities together. There
were no significant heterogeneities for all the toxicity analy-
ses except neutropenia; therefore, the pooled ORs were per-
formed using random-effort model for hematological toxici-
ties and fixed-effort model for nonhematological toxicities.
DISCUSSION
The current standard chemotherapy for E-SCLC is the EP
regimen. This regimen provides response rates of 60 to 80%,
with median survival time of 8 to 10 months. In JCOG 9511,
Noda et al.5 first reported a phase III study of IP compared with
EP regimen in 154 patients with E-SCLC. They found signifi-
cant differences in OS and toxicity profile in favor of the
irinotecan arm in an interim analysis and prematurely closed the
study. Hermes et al.6 and Schmittel et al.7 also found IP im-
proved OS and PFS in E-SCLC, respectively. However, another
larger study undertaken in the United States, Australia, and
Canada failed to confirm the positive results.8 Why did the larger
study fail to confirm the positive JCOG results? One explanation
might be that there was little difference in dose and schedule of
IP and EP. To answer this question, the Southwest Oncology
Group (SWOG) designed another phase III randomized con-
trolled trial (SWOG 0124) in North American patients with
E-SCLC, in which both the dose and schedule of IP and EP were
the same with JCOG 9511. Unfortunately, SWOG 0124 also
failed to confirm the positive results.9 Could these divergent
results create the pharmacogenomics difference between Japa-
nese and American populations? SWOG 0124 examined differ-
ent allelic variants in genes associated with irinotecan metabo-
lism and found that ABCB1 (C3435T) T/T and UGT1A1
(G-3156) A/A were associated with an increased risk of IP-
related diarrhea and neutropenia, respectively.9 However, none
of the genotypes were found to be associated with efficacy
outcomes. This debate motivated this meta-analysis.
Our results showed that IP regimens acquired more over-
all response and longer survival than EP regimens in patients
with previously untreated E-SCLC, but the subgroup meta-
analysis and sensitivity analysis after the trial using carboplatin
was excluded failed to show an advantage in IP regimens. The
IP and EP produced comparable PFS. In the two trials using
carboplatin combined with irinotecan comparing with carbopla-
tin combined with etoposide, Hermes et al.6 and Schmittel et al.7
found IP improved OS and PFS, respectively. Unfortunately,
Hermes et al. did not report PFS data and Schmittel et al. did not
report OS data. The two trials indicated that carboplatin com-
bined with irinotecan might be more effective than carboplatin
combined with etoposide.
Our results also showed that IP produced less grade 3 to 4
hematologic toxicity, but more grade 3 to 4 vomiting and
diarrhea, than EP. The toxicity results in present meta-analysis
agreed with preceding meta-analysis, which found that IP pro-
duced less grade 3 to 4 leukopenia, grade 3 anemia, grade 3 to
4 thrombocytopenia, but more grade 3 vomiting or nausea and
grade 3 to 4 diarrhea, than EP.21
Although the PFS was similar from this meta-analysis,
our results suggest that IP may have an advantage in overall
response and OS compared with EP with a different toxicity
profile. The IP regimens may be an alternative of EP regi-
mens in the first-line treatment of E-SCLC.
Although publication bias was not found according to
funnel plot, Begg’s test, and Egger’s test, these results need to
be interpreted very cautiously because there were only six
RCTs and some data were not reported and significant het-
erogeneity was seen between these studies according to OS
and PFS. The reasons for heterogeneity may be the different
race of the population, different drugs such as carboplatin in
place of cisplatin, and different dose intensity. The outcomes
from the two ongoing trials18,19 are eagerly awaited and a
further individual patient data meta-analysis was needed.
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